BSX financials
Boston Scientific Corporation · end-of-day data as of Oct 16, 2026
Boston Scientific Corporation
$44.39+0.3%
Buy · 32 analystsPT $66.64 +50.1%
BSX reported revenue of $5.44B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 7.5% from a year earlier. It posted diluted EPS of $0.61, free cash flow of $1.28B and a net margin of 16.7%.
Valuation
- P/E18.0x
- P/E vs own-50.4%
- P/E vs sector-35.9%
- FCF yield+5.6%
- Market cap$64.33B
Quarterly results
Q2 FY2026: Revenue +7.5% year over year, free cash flow 23.5% of revenue, operating margin 21.6%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $5.44B | 0.61 | $1.28B | 70.7% | 21.6% | 16.7% |
| Q1 FY2026 | Mar 31, 2026 | $5.2B | 0.90 | $171M | 69.4% | 20.6% | 25.7% |
| Q4 FY2025 | Dec 31, 2025 | $5.29B | 0.45 | $1.01B | 74.5% | 22.8% | 12.6% |
| Q3 FY2025 | Sep 30, 2025 | $5.07B | 0.50 | $1.16B | 69.9% | 20.7% | 14.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.06B | 0.53 | $1.1B | 67.7% | 16.2% | 15.7% |
| Q1 FY2025 | Mar 31, 2025 | $4.66B | 0.45 | $354M | 63.3% | 19.2% | 14.5% |
| Q4 FY2024 | Dec 31, 2024 | $4.56B | 0.38 | $1.16B | 58.6% | 12.9% | 12.4% |
| Q3 FY2024 | Sep 30, 2024 | $4.21B | 0.32 | $698M | 62.9% | 16.0% | 11.1% |
| Q2 FY2024 | Jun 30, 2024 | $4.12B | 0.22 | $658M | 62.7% | 18.1% | 7.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.86B | 0.33 | -$81M | 61.8% | 16.7% | 12.8% |
| Q4 FY2023 | Dec 31, 2023 | $3.73B | 0.34 | $690M | 62.1% | 15.0% | 13.5% |
| Q3 FY2023 | Sep 30, 2023 | $3.53B | 0.34 | $492M | 61.4% | 15.8% | 14.3% |